Goldman Sachs Initiates Coverage On Jazz Pharmaceuticals with Buy Rating, Announces Price Target of $169
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs has initiated coverage on Jazz Pharmaceuticals with a Buy rating and set a price target of $169.
June 05, 2024 | 12:24 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Goldman Sachs has initiated coverage on Jazz Pharmaceuticals with a Buy rating and set a price target of $169.
The initiation of coverage by a major financial institution like Goldman Sachs with a Buy rating and a specific price target is likely to positively influence investor sentiment and drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100